- Current languageen
Pharmaceuticals - Community Register
Community register of veterinary medicinal products
|Invented name:||Nobivac Bb|
|Auth. number :||EU/2/02/034|
|Active substance :||Not available|
|ATC:||Anatomical main group: QI - Immunologicals|
Therapeutic subgroup: QI06 - Immunologicals for felidae
Pharmacological subgroup: QI06A - Cat
Chemical subgroup: QI06AE - Live bacterial vaccines
Chemical substance: QI06AE02 - Bordetella
(See WHO ATCvet Index)
|Indication:||For active immunisation of cats, of 1 month of age or older to reduce clinical signs of Bordetella|
bronchiseptica associated upper respiratory tract disease.
Onset of immunity: Onset of immunity was established in 8 week old cats as early as 72 hours after
Duration of immunity: The duration of immunity is up to 1 year.
No data on the influence of maternal antibodies on the effect of vaccination with Nobivac Bb for cats are
available. From literature it is considered that this type of intranasal vaccine is able to induce an immune
response without interference from maternally derived antibodies.
|Marketing Authorisation Holder:||Intervet International B.V.
Wim de Körverstraat 35, NL-5831 AN Boxmeer, Nederland
|EPAR and active package presentations|
Information about presentations can be found in the website of the European Medicines Agency under the section "Product Information".|
Likewise, presentations on which there has been a Commission decision are referred in the Summary of Product Characteristics (Annex I to the Commission Decision granting the marketing authorisation) which is available in the Community Register.
|Close date procedure||Procedure type||EMEA number||Decision||summary publ||decision docs||annex|
|12/09/2002||Centralised - Authorisation||EMEA/V/C/68/1||(2002)3379 of 10/09/2002|
|11/04/2003||Centralised - Variation||EMEA/V/C/68/I/1||(2003)1247 of 09/04/2003|
|29/01/2004||Centralised - Variation||EMEA/V/C/68/II/2||(2004)219 of 27/01/2004|
|23/03/2004||Centralised - Notification||EMEA/V/C/68/N/3||(2004)1051 of 19/03/2004|
|29/11/2004||Centralised - Variation||EMEA/V/C/68/II/4||(2004)4626 of 25/11/2004|
|23/05/2005||Centralised - Variation||EMEA/V/C/68/IB/5|
|Updated with Decision(2006)154 of 20/01/2006|
|24/01/2006||Centralised - Variation||(2006)154 of 20/01/2006|
|27/09/2007||Centralised - Renewal||EMEA/V/C/68/R/6||(2007)4486 of 25/09/2007|
|25/07/2008||Centralised - Variation (no change in Commission Decision)||EMEA/V/C/68/II/7|
|25/07/2008||Centralised - Variation (no change in Commission Decision)||EMEA/V/C/68/II/8|
|08/06/2010||Centralised - Variation (no change in Commission Decision)||EMEA/V/C/68/IG/1|
|03/09/2012||Centralised - Renewal||EMEA/V/C/68/R/10||(2012)6134 of 30/08/2012|
|17/10/2014||Centralised - Variation||EMEA/V/C/68/IA/12|
|Updated with Decision(2015)7924 of 09/11/2015|
|11/11/2015||Centralised - Yearly update||(2015)7924 of 09/11/2015|